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ABSTRACT
Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis. Liver biopsy is considered the gold 
standard for assessment of fibrosis but this procedure is an invasive procedure. We aimed to evaluate the diagnostic efficiency of 
non-invasive serum biomarkers, separately and in combinations, on liver fibrosis in treatment-naive chronic hepatitis C (CHC) patients. 
Materials and Methods: Two hundred and sixteen treatment-naive CHC patients were enrolled from 32 locations across Turkey in this 
open-labelled, non-interventional prospective observational study. FibroTest®, aspartate aminotransferase-to-platelet ratio index(A-
PRI), aspartate aminotransferase and alanine aminotransferase ratio (AAR), fibrosis index based on four factors (FIB-4), Age-plate-
let(AP) index and Forns index were measured and compared with Metavir scores got from liver biopsies. 
Results: Data from 182 patients with baseline liver biopsy were suitable for analysis. One hundred and twenty patients (65.9%) had 
F0-F1 fibrosis and 62 patients (34.1%) had F2-F4 fibrosis. APRI 0.732 area under the curve(AUC) indicated advanced fibrosis with 69% 
sensitivity and 77% specificity. FIB-4 0.732 AUC and FibroTest 0.715 AUC indicated advanced fibrosis with 69% and 78.4% sensitivity, 
and 75% and 71.4% specificity, respectively. The combined use of tests also led to an increase in AUC and specificity. Combinations of 
FibroTest with APRI and/or FIB-4, and FIB-4 with APRI were optimal for the evaluation of liver fibrosis. 
Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC 
patients, and the use of at least two tests together will increase their diagnostic value still further. 
Keywords: Chronic hepatitis C infection, liver fibrosis, FibroTest, APRI, Forns index, Fib-4, non-invasive serum biomarkers 
INTRODUCTION
Hepatitis C virus (HCV) infection is a disease that affects 
approximately 2.8% of the world population and 1% of the 
Turkish population (1,2). The determination of hepatic fi-
brosis plays a significant role in treatment decisions and 
follow-up of chronic hepatitis C (CHC) patients (3). Liver 
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biopsy is the gold standard in the determination of hepat-
ic fibrosis; however, it is an invasive procedure, can result 
in serious complications, cannot be performed on every 
patient, and is difficult to repeat. Sampling errors, as well 
as differences of interpretation among pathologists, may 
occur (4-6). Currently, there are several noninvasive meth-
ods, such as serum biomarkers and imaging methods, for 
the assessment of liver fibrosis in CHC infection (7). Ul-
trasonography, magnetic resonance imaging, computed 
tomography, and transient elastography (TE-FibroScan) 
are examples of imaging methods. TE is the most recom-
mended diagnostic imaging method that measures liver 
stiffness; however, it is too expensive and is used only in 
a few hospitals in Turkey. Even more, the reimbursement 
agency does not pay the TE fee in Turkey. However, se-
rum biomarkers have numerous advantages, including the 
absence of risks, objective interpretation, patient accep-
tance, cost effectiveness, and the fact that they are easily 
applicable and repeatable tests (8). These biomarkers can 
be direct (collagen, hyaluronic acid, laminin, and YKL-40) 
and indirect [FibroTest (FT), ActiTest (AT), aspartate ami-
notransferase and alanine aminotransferase ratio (AAR), 
aspartate aminotransferase-to-platelet ratio index (APRI), 
four factors (FIB-4), age-platelet (AP) index, and Forns in-
dex]. Direct biomarkers are liver matrix components, the 
routine clinical use of which is limited. In contrast, indirect 
biomarkers are easy to perform serum-based tests, which 
include biochemical parameters routinely measured in 
the peripheral blood of CHC patients (9-12). These serum 
biomarkers have successfully identified hepatic fibrosis 
in CHC patients, but noninvasive serum biomarkers have 
some limitations, such as low accuracy of discrimination 
between intermediate stages of fibrosis. The diagnostic 
performance of serum biomarkers can be increased when 
these are used in combination in the determination of he-
patic fibrosis (3).
In this study, the diagnostic performances of serum bio-
markers such as FT, APRI, AAR, FIB-4, the AP index, and 
the Forns index were analyzed separately and in combi-
nation in treatment-naïve CHC patients. The results were 
compared with those from liver biopsy in terms of pre-
dicting fibrosis.
MATERIALS AND METHODS
In this noninterventional, observational study, 216 treat-
ment-naïve CHC patients aged between 18 and 65 years 
from 32 locations in Turkey were included. The study pa-
tients were anti-HCV positive for at least 6 months and 
had detectable levels of HCV-RNA by PCR for CHC. The 
patient recruitment began on November 1, 2008, and 
it continued for 24 months after approval of the ethics 
committee. Informed consent was obtained from all pa-
tients before starting any procedure.
Patients co-infected with HIV or hepatitis B virus, patients 
with suspected hepatocellular carcinoma or acquired/in-
herited liver disease, patients with a serious concomitant 
disease (renal failure, hypertension, DM, etc.), patients using 
immunosuppressive drugs during the previous 6 months, 
patients with abnormal hematological parameters that con-
traindicated liver biopsy (prolonged prothrombin time, low 
platelet count, etc.), and patients who used alcohol regard-
less of duration and who abused drugs were excluded from 
the study. Demographic, clinical, histological, and laboratory 
data were recorded.
Percutaneous liver biopsy was performed using a dispos-
able Hepafix suction needle (B. Braun, Melsungen, Germa-
ny). The same pathologist examined all liver biopsy samples. 
The stage of fibrosis was determined using the METAVIR 
scoring system (13). Two groups were established based 
on fibrosis scores: Group 1, F0-F1 (no fibrosis) and Group 
2, F2-F4 (significant/advanced fibrosis). Blood samples for 
serum biomarkers were collected simultaneously with the 
liver biopsy procedure and stored at −80°C until analysis.
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Serum Biomarkers Methods
Fibrotest® (FT) (Biopredictive, Paris, France) Patented  
 formula combining α-2-macroglobulin, 
 γGT, apolipoprotein A1, haptoglobin,  
 total bilirubin, age, and gender
Forns Index 7.811−3.131×(platelet count)+0.781 ×  
 (GGT)+3.467×(age)−0.014× 
 (cholesterol)
AST to Platelet AST (Upper Limit of Normal) (IU/L)/ 
Ratio (APRI) platelet (109/L)×100
FIB-4 [Age (year)×AST (IU/L)]/[platelet  
 (109/L)×√ALT (IU/L)]
Age-platelet Age (year) (<30=0; 30-39=1; 40- 
(AP) index 49=2; 50-59=3; 60-69=4; ≥70=5) +  
 platelet (109/L) (≥225=0; 200-224=1;  
 175-199=2; 150-174=3; 125-149=4;  
 <125=5)
AST/ALT ratio (AAR) AST (IU/L)/ALT (IU/L)
APRI: aspartate aminotransferase-to-platelet ratio index; FIB-4: fibrosis 
index based on four factors; AST: aspartate aminotransferase; ALT: 
alanine aminotransferase
Table 1. Noninvasive serum biomarker methods
Noninvasive serum biomarkers, FT, APRI, AAR, FIB-4, the 
AP index, and the Forns index were calculated for all pa-
tients using laboratory data based on a single center with 
the formulas shown in Table 1 (8,9,11,14-20).
The following combinations were calculated simulta-
neously: FibroTest+APRI, FibroTest+APRI+FIB-4, Fi-
broTest+FIB-4, FibroTest+AP index, FibroTest+Forns 
index, FibroTest+AAR, APRI+FIB-4, APRI+AP index, 
APRI+AAR, APRI+Forns index, FIB-4+AP index, FIB-
4+AAR, FIB-4+ Forns index, AP index+AAR, AP index+-
Forns index, and AAR+Forns index.
Statistical analysis
Descriptive statistical analysis was conducted using the 
Statistical Package for Social Sciences (SPSS) 13.0 soft-
ware (SPSS Inc.; Chicago, IL, USA). Data were expressed 
as mean±standard deviation (SD), percentage (%), or 
median (min-max), as appropriate. p-values of <0.05 
were considered statistically significant. Categorical 
data were analyzed using the Chi-squared and Fisher’s 
tests. Data obtained in measurements of normal distri-
bution were analyzed using the Kolmogorov-Smirnov 
test. Data conforming to normal distribution were an-
alyzed using the Student’s-t test, and non-conforming 
data were analyzed using the Mann-Whitney U test. 
Correlation analysis was performed using the Spear-
man’s correlation test. The receiver operating charac-
teristic (ROC) analysis was performed to calculate the 
sensitivity, specificity, negative predictive value (NPV), 
and positive predictive value (PPV) of the noninvasive 
serum biomarkers for the prediction of hepatic fibrosis.
RESULTS
Of the 216 patients recorded in this study, 182 (84.3%) 
were eligible for assessment. Thirty-four patients were 
excluded from the analysis due to insufficient liver biopsy 
samples, absence of one or more laboratory parameters, 
or missing data entry.
The mean (SD) age was 49.9±11.4 years, and 59.9% of 
the 182 patients were female. One hundred and twenty 
(65.9%) patients were classified as having METAVIR fi-
brosis stage F0-F1 (no fibrosis; Group 1) and 62 (34.1%) 
patients as having F2-F4 (significant/advanced fibrosis; 
Group 2). Patients with higher fibrosis scores were ob-
served to have a higher average age, indicating that ad-
vanced age was correlated with higher fibrosis (p=0.003). 
No statistical significance was observed between gen-
der and fibrosis. The patients with advanced fibrosis had 
higher mean ALT and AST values (p<0.005). Although 
platelet counts were lower in patients with advanced fi-
brosis, no statistically significant difference was observed 
compared with patients with no fibrosis (p=0.053). There 
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Serum Biomarkers Methods
Mean age   48.4±12.2 53.1±9.0 0.003
Gender, n (M/F)  45/75 30/32 0.193
Mean AST, U/L  43.2±32.5 65.7±48.2 0.000
Mean ALT, U/L  60.2±55.6 77.5±62.6 0.004
Mean platelet count (×103/microL) 235.4±57.7 215.9±71.0 0.053
Protein  7.6±0.5 7.5±0.5 0.327
Albumin  4.3±0.6 4.3±0.5 0.654
APRI  0.51±0.5 0.95±1.2 0.000
AAR  0.85±0.3 1.03±0.6 0.060
FIB-4  1.30±0.9 2.35±2.1 0.000
AP index  4.59±1.7 5.41±1.7 0.002
Forns index  4.37±1.6 5.28±2.0 0.034
 F0 31 9
FibroTest F1-F2 40 20 0.003
 F3 15 9
 F4 5 13 
AST: aspartate aminotransferase; ALT: alanine aminotransferase; APRI: aspartate aminotransferase-to-platelet ratio index; AAR: AST/ALT ratio; FIB-4: 
fibrosis index based on four factors; AP index: age-platelet index
Table 2. Demographic features and laboratory parameters of the 182 patients
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 Cutoff    p AUC Sensitivity (%) Specificity (%) NPV (%) PPV (%)
APRI >0.5 0.0001 0.732 69.0 77.0 81.1 63.5
AAR >1.0 0.059 0.589 37.3 79.8 69.2 51.2
FIB-4 >1.5 0.0001 0.732 69.0 75.0 80.6 61.5
AP index ≥6 0.002 0.639 54.2 70.7 75.2 48.5
Forns index >5 0.045 0.629 56.7 68.3 75.9 47.2
Fibrotest ≥F2 0.0001 0.715 78.4 71.4 85.5 60.6
Fibrotest ≥F2  








+  0.0001 0.719 62.5 81.3 81.2 62.5 
FIB-4 >1.5
Fibrotest ≥F2 
+  0.018 0.616 43.1 80.0 74.3 51.2 
AP index >6
Fibrotest ≥F2 
+  0.132 0.597 37.9 81.4 76.0 45.8 
Forns index >5
Fibrotest ≥F2 
+  0.148 0.571 26.4 87.9 69.0 53.8 
AAR >1.0
APRI >0.5 
+  0.0001 0.740 62.1 86.0 79.6 72.0 
FIB-4 >1.5
APRI >0.5 
+  0.0001 0.689 47.5 90.3 76.7 71.8 
AP index >6
APRI >0.5 
+  0.0094 0.621 27.1 97.1 69.9 84.2 
AAR >1.0
APRI >0.5 
+  0.0364 0.599 25.9 94.0 68.6 71.4 
Forns index >5
FIB-4 >1.5 
+  0.0001 0.687 54.2 83.2 77.7 62.7 
AP index >6
FIB-4 >1.5 
+  0.0119 0.617 32.2 91.3 70.1 67.9 
AAR >1.0
FIB-4 >1.5 
+  0.0055 0.658 44.4 87.2 77.3 61.5 
Forns index >5 
AP index >6 
+  0.0317 0.599 28.3 91.4 71.1 63.0 
AAR >1.0
AP index >6 
+  0.0446 0.606 34.9 86.3 75.9 51.7 
Forns index >5
AAR >1.0 
+  0.238 0.570 22.2 91.8 70.5 57.1 
Forns index >5
NPV: negative predictive value; PPV: positive predictive value; APRI: aspartate aminotransferase-to-platelet ratio index; AAR: AST/ALT ratio; FIB-4: 
fibrosis index based on four factors; AP index: age-platelet index
Table 3. Sensitivity, specificity, and predictive values of serum biomarkers either alone or combined
was a significant difference in terms of APRI, FIB-4, the 
AP index, and the Forns index between the two groups 
(p<0.05). This finding shows that APRI, FIB-4, the AP in-
dex, and the Forns index are important serum biomarkers 
in the determination of liver fibrosis (Table 2). AAR was 
not significant in the determination of the stage of fibro-
sis. The correlation between the METAVIR fibrosis scores 
and FibroTest results (r=0.321; p<0.001) increased with 
the stage of fibrosis.
METAVIR fibrosis scores and FibroTest (r=0.321; 
p<0.001), APRI (r=0.302; p<0.001), the Forns index 
(r=0.339; p=0.001), and the AP index (r=0.254; p=0.001) 
results were also positively correlated.
The ROC analysis of noninvasive tests revealed that the 
area under the curve (AUC) exceeded the reference line 
in the majority of tests (Figure 1). The APRI 0.732 AUC in-
dicated advanced fibrosis with 69% sensitivity and 77% 
specificity. The FIB-4 0.732 AUC and FibroTest 0.715 
AUC indicated advanced fibrosis with 69% and 78.4% 
sensitivity and 75% and 71.4% specificity, respectively. 
The combined use of tests also led to an increase in AUC 
and specificity. A combination of FibroTest with APRI 
and/or FIB-4 and of APRI with FIB-4 was identified to be 
optimal for the assessment of fibrosis (Table 3). The er-
ror bar graph analysis of noninvasive tests showed that 
FibroTest, APRI, and FIB-4 could be used to differentiate 
patients with advanced fibrosis from patients with mini-
mal fibrosis (Figure 2-7).
DISCUSSION
Liver biopsy is the gold standard method for the determina-
tion of hepatic fibrosis, but it has many disadvantages, such 
as side effects, patient reluctance, inadequate sample, eval-
uation errors, and high cost (21,22). These limitations have 
led to the development of noninvasive alternative methods 
for the evaluation of liver fibrosis. These methods can be 
summarized as serum biomarkers and imaging methods for 
the assessment of liver fibrosis in CHC infection (7). TE is 
the most recommended diagnostic imaging method that 
measures liver stiffness, as mentioned in the introductory 
section. In many studies comparing the performance of TE 
and serum biomarkers mostly in viral hepatitis, it has been 
found that TE and serum biomarkers have equal perfor-
mance for detecting significant fibrosis (20). Although the 
combination of TE and serum biomarkers is more effective 
than the combination of two serum biomarkers for a signif-
icant fibrosis finding, it is more expensive when compared 
with serum biomarkers (20). However, serum biomarkers 
have emerged as a leading methodology, as these tests are 
repeatable, noninvasive, and cost-effective. The costs of 
these tests vary, FibroTest being the most expensive. The 
others can be easily calculated using equations involving the 
patient’s routine biochemical tests. Serum biomarkers are 
recommended by the American Association for the Study 
of Liver Diseases, the European Association for the Study 
of the Liver, and the World Health Organization for deter-
mining stage of fibrosis in patients with HCV infection in 
the light of these advantages (23-25). However, these tests 
may exhibit low accuracy in differentiating intermediate 
or low stages of fibrosis from increased stages of fibrosis. 
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Figure 1. ROC curve analysis of noninvasive tests for diagnosis of liver fibrosis
Figure 2. Error bar graphic images of FibroTest for diagnosis of liver fibrosis
In addition, interpreting the results may be difficult since 
various stages of fibrosis have different cutoff values. The 
validation of serum biomarkers for evaluating fibrosis is of 
critical importance for the routine clinical use of these tests. 
When applied individually in cases of significant fibrosis, the 
diagnostic value of these tests does not exceed 80%. For 
this reason, considering more than one serum biomarker 
can increase the susceptibility of the tests.
The data collected from the 182 enrolled patients clearly 
showed that fibrosis scores increase with age (p=0.003). 
This may be attributed to infection with HCV at an early 
age that remained untreated for many years due to a lack 
of patient awareness. The advanced age may thus have 
affected the efficacy of noninvasive tests, particularly 
FIB-4, the AP index, and the Forns index, in the determi-
nation of fibrosis (Table 2). Significant differences were 
observed in the APRI, FIB-4, AP index, and Forns index 
values between the fibrosis groups (p<0.05), indicating 
that APRI, FIB-4, the AP index, and the Forns index are 
important serum biomarkers for the determination of 
significant fibrosis. A positive correlation was observed 
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Figure 3. Error bar graphic images of APRI for diagnosis of liver fibrosis Figure 5. Error bar graphic images of the Forns index for diagnosis of liver fibrosis
Figure 4. Error bar graphic images of FIB-4 for diagnosis of liver fibrosis Figure 6. Error bar graphic images of the AP index for diagnosis of liver fibrosis
between APRI, FIB-4, the AP index, and the Forns index 
and the METAVIR fibrosis scores. There was also a posi-
tive correlation between FibroTest and fibrosis. Sensitiv-
ity analysis showed that the FibroTest demonstrated the 
highest sensitivity, 78.4%, followed by APRI, FIB-4, the 
Forns index, and the AP index. AAR exhibited the lowest 
sensitivity, although no statistically significant difference 
was observed between the groups. The specificity values 
of all tests were close to one another. NPV was higher than 
PPV in all tests in this study. The AUC values were similar, 
the highest values being observed in the APRI, FIB-4, and 
FibroTest tests. The AUC, sensitivity, specificity, NPV, and 
PPV from noninvasive tests were similar to or lower than 
those reported in the original publications for those tests 
(9,17,26-31). Wai et al. (9) reported that APRI PPV for the 
determination of significant fibrosis was higher than NPV. 
AUC was reported at 0.80. However, the opposite was 
observed in the present study, in which NPV was high-
er than PPV. This difference may be attributable to the 
use of the Ishak score by Wai et al. (9) for fibrosis scoring, 
as well as the greater number of patients with cirrhosis 
and advanced fibrosis in that study. In the meta-analysis 
by Lin et al. (11), for the prediction of significant fibrosis, 
the estimated PPV and NPV of the 0.5 cutoffs were 55% 
and 69%, respectively. At the 1.5 cutoff, the estimated 
PPV and NPV were 82% and 63%, respectively. At the 0.7 
cutoff, the estimated PPV and NPV were 70% and 79%, 
respectively. PPV and NPV of APRI for the prediction of 
significant fibrosis differ at various thresholds. In this 
meta-analysis, the best cutoff for diagnosing significant 
fibrosis was 0.7, whereas for diagnosing cirrhosis it was 
1. In our study, at the 0.5 cutoff, the estimated PPV and 
NPV of APRI were 63.5% and 81.1%, respectively. In oth-
er studies, for investigating the diagnostic performance 
of APRI, different results have been reported for the es-
timated significant fibrosis and cirrhosis (28-30). In the 
study of Leroy et al. (32), when >0.5 cutoff was used for 
APRI in the diagnosis of significant fibrosis (F2-F4), the 
specificity was found to be only 26.8%; however, when 
>1.5 cutoff was used, the specificity was found to be 
87.8%. At the same time, the concomitant presence of 
FibroTest>0.59 and APRI>2 improved PPV for significant 
fibrosis to 96.7% and for extensive fibrosis to 92.2%. The 
fact that our results are different from study results of 
Leroy et al. (32) may be due to the low number of pa-
tients with advanced fibrosis. Our study concluded that 
APRI had better performance for mild fibrosis.
While the FIB-4 AUC and sensitivity values in this study 
were parallel to those reported by Sterling et al. (27), the 
NPV value was higher. However, it should be noted that 
Sterling et al. (27) investigated patients co-infected with 
HCV/HIV and used the Ishak score for fibrosis scoring. In 
a study by Vallet-Pichard et al. (26), the FIB-4 index en-
abled the correct identification of patients with severe 
fibrosis (METAVIR F3-F4) with a 0.85 AUC. An FIB-4 in-
dex lower than 1.45 had an NPV of 94.7% to exclude any 
extensive fibrosis (F3-F4) with a sensitivity of 74.3% and 
a specificity of 80.1%. A higher FIB-4 index (>3.25) was 
recommended to confirm the existence of significant fi-
brosis. In our study, an FIB-4 index higher than 1.5 had 
PPV and NPV of 61.5% and 80.6%, respectively, with a 
sensitivity of 69% and a specificity of 80.1%.
Noninvasive tests exhibited improved diagnostic per-
formance in patients with advanced fibrosis (17,29,31). 
The poor performance of noninvasive tests in this re-
search compared with that of the original studies may 
be attributed to the fact that only 34% of patients had 
serious fibrosis and that the number of patients with cir-
rhosis was low. Recently, several studies have shown that 
the diagnostic performance of serum biomarker tests 
increases significantly when these are used in combina-
tion (33-36). Mummadi et al. (10) showed that there was 
a significant correlation between change in the stage of 
fibrosis and change in APRI and FIB-4. In this study, APRI 
had a positive predictive value (PPV) of 67% and a nega-
tive predictive value of 67% (NPV) for progression of fi-
brosis. As for FIB-4, PPV and NPV were 75%. The results 
of our study are similar, with a specificity of >80% being 
observed when the tests were used in combination. The 
combination of FibroTest with APRI and/or FIB-4 and 
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Figure 7. Error bar graphic images of AAR for diagnosis of liver fibrosis
APRI with FIB-4 exhibited good diagnostic performance 
for determining significant fibrosis. The FibroTest is more 
expensive than other serum biomarkers, and the use of 
APRI or FIB-4 is therefore recommended for the detec-
tion of hepatic fibrosis, particularly when resources are 
limited (25). However, none of these tests are of equal 
value in the assessment of both fibrosis and cirrhosis. For 
instance, APRI has been successfully validated for the di-
agnosis of both significant fibrosis and cirrhosis, whereas 
FIB-4 is useful only for the diagnosis of significant fibrosis 
(METAVIR stage≥F2) (25). One of the greatest advantages 
of combining tests is the resulting decrease in diagnostic 
differences. This decrease in diagnostic differences with 
the use of serum biomarker tests is clearly demonstrated 
in the present study. Our results show that the specificity 
of tests increases when these are used together.
In conclusion, there is a consistent and growing need for 
easily reproducible tests for the effective diagnosis of ad-
vanced hepatic fibrosis. Studies comparing the efficacies 
of liver biopsy and noninvasive tests provide guidance for 
the development and introduction of new techniques. 
This study concludes that APRI, FIB-4, AP index, Forns 
index, and FibroTest, as well as the combined use of these 
tests, can help identify CHC patients with significant/ad-
vanced fibrosis. However, none of the parameters accord-
ing to cutoff points have a good diagnostic performance. 
The concurrent use of at least two of these tests will be 
useful for the evaluation and follow-up of CHC patients 
with fibrosis. In particular, the use of FIB-4 and APRI to-
gether may be indicative of significant/advanced fibrosis.
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